Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors

References

• Acevedo-Morantes CY, Acevedo-Morantes MT, Suleiman-Rosado D, Ramírez-Vick JE. (2013). Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells. Drug Deliv 20:338–48
   PubMed Web of Science ®Google Scholar
• Basili S, Moro S. (2009). Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin Ther Pat 19:555–74
   PubMed Web of Science ®Google Scholar
• Broecker-Preuss M, Müller S, Britten M, et al. (2015). Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer 15:184
   PubMed Web of Science ®Google Scholar
• Campanella P, Ianni F, Rota CA, et al. (2014). Quantification of cancer risk of each clinical and ultrasonographic suspicious feature of thyroid nodules: a systematic review and meta-analysis. Eur J Endocrinol 170:R203–11
   PubMed Web of Science ®Google Scholar
• Chen ED, Cheng P, Yan XQ, et al. (2014). Metastasis of distal esophageal carcinoma to the thyroid with presentation simulating primary thyroid carcinoma: a case report and review of the literature. World J Surg Oncol 12:106
   PubMed Web of Science ®Google Scholar
• Chourpa I, Riou JF, Millot JM, et al. (1998). Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA. Biochemistry 37:7284–91
   PubMed Web of Science ®Google Scholar
• Cornett WR, Sharma AK, Day TA, et al. (2007). Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 9:152–58
   PubMedGoogle Scholar
• Denaro N, Nigro CL, Russi EG, Merlano MC. (2013). The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther 6:1231–41
   Google Scholar
• Desai SD, Li TK, Rodriguez-Bauman A, et al. (2001). Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61:5926–32
   PubMed Web of Science ®Google Scholar
• Dianzani C, Minelli R, Mesturini R, et al. (2010). B7h triggering inhibits umbilical vascular endothelial cell adhesiveness to tumor cell lines and polymorphonuclear cells. J Immunol 185:3970–9
   PubMed Web of Science ®Google Scholar
• Dianzani C, Minelli R, Gigliotti CL, et al. (2014). B7h triggering inhibits the migration of tumor cell lines. J Immunol 192:4921–31
   PubMed Web of Science ®Google Scholar
• Faam B, Ghaffari MA, Ghadiri A, Azizi F. (2015). Epigenetic modifications in human thyroid cancer. Biomed Rep 3:3–8
   PubMed Web of Science ®Google Scholar
• Fassberg J, Stella VJ. (1992). A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676–84
   PubMed Web of Science ®Google Scholar
• Fukushima T, Takenoshita S. (2005). Roles of RAS and BRAF mutations in thyroid carcinogenesis. Fukushima J Med Sci 51:67–75
   PubMedGoogle Scholar
• Gigliotti CL, Minelli R, Cavalli R, et al. (2016a). In vitro and in vivo therapeutic evaluation of camptothecin-encapsulated ß-cyclodextrin nanosponges in prostate cancer. J Biomed Nanotechnol 12:114–27
   PubMed Web of Science ®Google Scholar
• Gigliotti CL, Boggio E, Clemente N, et al. (2016b). ICOS-ligand triggering impairs osteoclast differentiation and function in vitro and in vivo. J Immunol 197:3905–16
   PubMed Web of Science ®Google Scholar
• Gilliland FD, Hunt WC, Morris DM, Key CR. (1997). Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564–73
   PubMed Web of Science ®Google Scholar
• Huang TT, Wuerzberger-Davis SM, Seufzer BJ, et al. (2000). NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 275:9501–9
   PubMed Web of Science ®Google Scholar
• Jayasooriya RG, Park SR, Choi YH, et al. (2011). Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-κB activity and Nrf2-dependent induction of HO-1 expression. Environ Toxicol Pharmacol 39:1189–98
   Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin 61:134
   Web of Science ®Google Scholar
• Kim YS, Noh MY, Kim JY, et al. (2013). Direct GSK-3β inhibition enhances mesenchymal stromal cell migration by increasing expression of β-PIX and CXCR4. Mol Neurobiol 47:811–20
   PubMed Web of Science ®Google Scholar
• Knauf JA, Fagin JA. Curr (2009). Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin. Cell Biol 21:296–303
   PubMed Web of Science ®Google Scholar
• Li J, Chen F, Cona MM, et al. (2012). A review on various targeted anticancer therapies. Target Oncol 7:69–85
   PubMed Web of Science ®Google Scholar
• Lim YC, Cha YY. (2011). Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex. J Surg Oncol 104:776–80
   PubMed Web of Science ®Google Scholar
• Ma J, Waxman DJ. (2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7:3670–84
   PubMed Web of Science ®Google Scholar
• Marotta V, Guerra A, Sapio MR, Vitale M. (2011). RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol 165:499–507
   PubMed Web of Science ®Google Scholar
• Minelli R, Cavalli R, Ellis L, et al. (2012a). Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. Eur J Pharm Sci 47:686–94
   PubMed Web of Science ®Google Scholar
• Minelli R, Serpe L, Pettazzoni P, et al. (2012b). Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. Br J Pharmacol 166:587–601
   PubMed Web of Science ®Google Scholar
• Mirrielees JA, Kapur JH, Szalkucki LM, et al. (2014). Metastasis of primary lung carcinoma to the breast: a systematic review of the literature. J Surg Res 188:419–31
   PubMed Web of Science ®Google Scholar
• Occhipinti S, Dianzani C, Chiocchetti A, et al. (2013). Triggering of B7h by the ICOS modulates maturation and migration of monocyte-derived dendritic cells. J Immunol 190:1125–34
   PubMed Web of Science ®Google Scholar
• Parenti R, Salvatorelli L, Magro G. (2014). Anaplastic thyroid carcinoma: current treatments and potential new therapeutic options with emphasis on TfR1/CD71. Int J Endocrinol 2014:685396
   PubMed Web of Science ®Google Scholar
• Passaro C, Borriello F, Vastolo V, et al. (2016). The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget 7:1500–15
   PubMed Web of Science ®Google Scholar
• Patel KN, Shaha AR. (2006). Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13:119–28
   PubMedGoogle Scholar
• Perri F, Pezzullo L, Chiofalo MG, et al. (2015). Targeted therapy: a new hope for thyroid carcinomas. Crit Rev Oncol/Hematol 94:55–63
   PubMed Web of Science ®Google Scholar
• Phay JE, Ringel MD. (2013). Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer 20:R307–19
   PubMed Web of Science ®Google Scholar
• Ragazzi M, Ciarrocchi A, Sancisi V, et al. (2014). Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol 2014:790834
   PubMed Web of Science ®Google Scholar
• Raman P, Koenig RJ. (2014). Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Rev Endocrinol 10:616–23
   PubMed Web of Science ®Google Scholar
• Romei C, Elisei R. (2012). RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma. Front Endocrinol (Lausanne) 3:54
   PubMedGoogle Scholar
• Schweppe RE, Klopper JP, Korch C, et al. (2008). Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331–41
   PubMed Web of Science ®Google Scholar
• Stevens BM, Folts CJ, Cui W, et al. (2014). Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo. Stem Cells 32:1124–35
   PubMed Web of Science ®Google Scholar
• Subramanian S, Singireddy A, Krishnamoorthy K, Rajappan M. (2012). Nanosponges: a novel class of drug delivery system-review. J Pharm Pharm Sci 15:103–11
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Pastero L, Serpe L, et al. (2010). Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 74:193–201
   PubMed Web of Science ®Google Scholar
• Torne S, Darandale S, Vavia P, et al. (2013). Cyclodextrin-based nanosponges: effective nanocarrier for tamoxifen delivery. Pharm Dev Technol 18:619–25
   PubMed Web of Science ®Google Scholar
• Trotta F, Dianzani C, Caldera F, et al. (2014). The application of nanosponges to cancer drug delivery. Expert Opin Drug Deliv 11:931–41
   PubMed Web of Science ®Google Scholar
• Varinot J, Ménégaux F, Bitker MO, Compérat E. (2014). Renal metastasis from thyroid carcinoma: a case report. Anal Quant Cytopathol Histpathol 36:46–50
   PubMed Web of Science ®Google Scholar
• Wall ME, Wani MC, Cook CE, et al. (1966). Plant antitumor agent I: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J Am Chem 88:3888–90
   Web of Science ®Google Scholar
• Wang M, Thanou M. (2010). Targeting nanoparticles to cancer. Pharmacol Res 62:90–9
   PubMed Web of Science ®Google Scholar
• Wein RO, Weber RS. (2011). Anaplastic thyroid carcinoma: palliation or treatment?. Curr Opin Otolaryngol Head Neck Surg 19:113–8
   PubMed Web of Science ®Google Scholar
• Xie X, Lin W, Liu H, et al. (2016). Ultrasound-responsive nanobubbles contained with peptide-camptothecin conjugates for targeted drug delivery. Drug Deliv 23:2756–64
   PubMed Web of Science ®Google Scholar
• Yang A, Liu Z, Yan B, et al. (2016). Preparation of camptothecin-loaded targeting nanoparticles and their antitumor effects on hepatocellular carcinoma cell line H22. Drug Deliv 23:1699–706
   PubMed Web of Science ®Google Scholar